Latest News and Press Releases

Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s disease (PD) support P2B001 as a first line, once-daily treatment choice for...

REHOVOT, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Leading KOLs Dr. Robert Hauser and Dr. Warren Olanow will discuss the unmet medical need in early-stage PD and the uniquely favorable efficacy and safety profile of P2B001 Results demonstrate...

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a...

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed...

Myung In Pharm to lead registration, commercialization and manufacturing of P2B001 in South Korea Myung In Pharm made a $5 million equity investment in Pharma Two B REHOVOT, Israel, Nov. ...

REHOVOT, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD),...

REHOVOT, Israel, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today...

REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today...

REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, today...